May 24, 2019 / 11:39 PM / 2 months ago

BRIEF-FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

May 24 (Reuters) - Incyte Corp:

* FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

* INCYTE CORP - JAKAFI WILL BE MADE AVAILABLE TO APPROPRIATE PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD IMMEDIATELY.

* INCYTE CORP - FDA APPROVED JAKAFI (RUXOLITINIB) FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below